Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
Period End Date | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 |
Revenues | -- | -- | -- | -- | -- | 2,606.57 | 2,340.20 | 2,066.74 | 1,838.71 | 1,678.91 |
Revenue-Sleep and Respiratory Care products | 4,101.17 | 3,725.02 | 3,177.30 | 2,823.24 | 2,602.38 | -- | -- | -- | -- | -- |
Revenue-Software as a Service | 584.13 | 497.98 | 400.83 | 373.59 | 354.63 | -- | -- | -- | -- | -- |
Total Revenues | 4,685.30 | 4,222.99 | 3,578.13 | 3,196.83 | 2,957.01 | 2,606.57 | 2,340.20 | 2,066.74 | 1,838.71 | 1,678.91 |
Cost of sales | -- | -- | -- | -- | -- | 1,069.99 | 978.03 | 864.99 | 772.22 | 667.52 |
Voluntary product recall expenses | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Cost of sales-Sleep and Respiratory Care products | 1,806.85 | 1,662.96 | 1,365.42 | 1,177.31 | 1,067.97 | -- | -- | -- | -- | -- |
Cost of sales-Software as a Service | 190.19 | 173.98 | 148.75 | 135.29 | 121.66 | -- | -- | -- | -- | -- |
Amortization of acquired intangible assets-Sleep and Respiratory Care products | 5.52 | 5.34 | 4.11 | 4.90 | 8.58 | -- | -- | -- | -- | -- |
Amortization of acquired intangible assets-Software as a Service | 27.45 | 25.06 | 35.55 | 40.23 | 41.02 | -- | -- | -- | -- | -- |
Gross Profit | 2,655.30 | 2,355.66 | 2,024.31 | 1,839.10 | 1,717.79 | 1,536.59 | 1,362.16 | 1,201.75 | 1,066.50 | 1,011.40 |
Amortization of acquired intangible assets | 46.52 | 42.02 | 31.08 | 31.08 | 30.09 | 74.94 | 46.38 | 46.58 | 23.92 | 8.67 |
Research and development | 307.53 | 287.64 | 253.58 | 225.28 | 201.95 | 180.65 | 155.15 | 144.47 | 118.65 | 114.87 |
In-process research and development charge (note 20) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Education, research and settlement charge | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Selling, general and administrative | 917.14 | 874.00 | 739.37 | 670.39 | 676.69 | 645.01 | 600.37 | 553.97 | 488.06 | 478.63 |
Restructuring expenses | 64.23 | 9.18 | -- | 8.67 | -- | 9.40 | 18.43 | 12.36 | 6.91 | -- |
Donations to Research Foundations | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Acquisition expenses | -- | (10.95) | -- | -- | -- | (6.12) | -- | (10.08) | -- | -- |
Litigation settlement expenses | -- | -- | -- | -- | 0.60 | (41.20) | -- | (8.50) | -- | -- |
Total Operating Expenses | 1,335.41 | 1,223.79 | 1,024.03 | 935.42 | 908.13 | 957.32 | 820.33 | 775.95 | 637.55 | 602.16 |
Operating Income (Loss) | 1,319.89 | 1,131.87 | 1,000.29 | 903.68 | 809.66 | 579.26 | 541.83 | 425.80 | 428.95 | 409.24 |
Interest expense | 45.71 | 47.38 | 22.31 | 23.99 | 40.38 | 36.16 | 28.36 | 28.24 | 11.21 | 5.78 |
Loss attributable to equity method investments | (1.85) | (7.27) | (8.49) | (11.21) | (25.06) | (15.83) | -- | -- | -- | -- |
Gain (loss) on equity investments (note 5) | (4.05) | 9.92 | (12.20) | -- | -- | -- | -- | -- | -- | -- |
Interest income (expense), net | -- | -- | -- | 0.36 | 1.02 | 2.30 | 16.38 | 17.09 | 16.86 | 26.21 |
Other, net | (3.49) | (5.71) | 3.20 | 14.82 | (12.16) | (10.73) | (8.54) | 4.10 | 4.96 | 6.25 |
Gain (loss) on extinguishment of debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Government grants | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: License fees | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Gain/(loss) on foreign currency hedging position | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Gain/(loss) on foreign currency transactions | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Other | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Realized gain on sale of marketable securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Impairment of cost method investment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Gain on sale of real property | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Gain on sale of plant and equipment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Other: Gain on sale of business assets and contracts | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Gain on insurance recoveries (1) | -- | 20.23 | -- | -- | -- | -- | -- | -- | -- | -- |
Total other income (expenses), net | (55.10) | (30.21) | -- | -- | -- | -- | -- | -- | -- | -- |
Pre-Tax Income - U.S | 181.11 | 128.59 | (85.92) | 71.87 | 60.55 | (34.47) | 42.63 | (4.99) | -- | -- |
Non-U.S | 1,083.69 | 973.08 | 1,046.40 | 811.80 | 672.54 | 553.32 | 478.69 | 423.73 | -- | -- |
Income before Income taxes | 1,264.80 | 1,101.66 | 960.48 | 883.66 | 733.09 | 518.85 | 521.31 | 418.74 | 439.57 | 435.92 |
Current: Federal | 57.10 | 36.63 | 4.38 | (115.11) | 9.79 | 28.66 | 128.97 | 16.47 | 24.33 | 28,429.00 |
Current: State | 17.25 | 14.14 | 10.70 | 9.04 | 6.90 | 7.60 | 0.95 | (1.16) | 5.81 | 695.00 |
Deferred: Federal | (22.92) | (21.72) | (12.61) | (22.79) | (13.00) | (30.46) | 9.49 | 11.39 | 5.64 | (4,269.00) |
Deferred: State | (4.63) | (2.39) | (2.77) | (4.21) | (3.34) | (5.41) | (0.35) | 2.71 | (1.64) | (180.00) |
Current- Non-U.S | 219.37 | 198.77 | 177.79 | 531.81 | 124.60 | 127.54 | 68.86 | 65.61 | 58.02 | 50,892.00 |
Deferred- Non-U.S | (22.33) | (21.32) | 3.57 | 10.41 | (13.54) | (13.67) | (2.19) | (18.55) | (4.99) | 7,463.00 |
Income taxes | 243.85 | 204.11 | 181.05 | 409.16 | 111.41 | 114.26 | 205.72 | 76.46 | 87.16 | 83.03 |
Net Income (Loss) Available to Common Shareholders | 1,020.95 | 897.56 | 779.44 | 474.51 | 621.67 | 404.59 | 315.59 | 342.28 | 352.41 | 352.89 |
Continuing Operations- (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Basic Earnings Per Share | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 | 2.51 | 2.51 |
Continuing Operations- (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Diluted Earnings Per Share | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 | 2.49 | 2.47 |
Weighted Average Shares Outstanding (Basic) | 147.02 | 146.77 | 146.07 | 145.31 | 144.34 | 143.11 | 142.76 | 141.36 | 140.24 | 140.47 |
Weighted Average Shares Outstanding (Diluted) | 147.55 | 147.46 | 147.04 | 146.45 | 145.65 | 144.48 | 143.99 | 142.45 | 141.67 | 142.69 |